PRESS-RELEASE ·Filed May 20, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor the May 27 event for data releases that could inform EQ504's development trajectory. Until then, no near-term catalyst is present.
Latest settled — T+20d
EQ ▲ +28.05% at T+20d
NEUTRAL call +28.05% · α vs SPY +27.72% · entry $2.21 → $2.83
T+1d
+2.26%
call +2.26% · α +1.82%
$2.26
settled 5mo ago
T+5d
+28.51%
call +28.51% · α +26.91%
$2.84
settled 5mo ago
T+20d
+28.05%
call +28.05% · α +27.72%
$2.83
settled 4mo ago
T+60d
Pending
due 2mo ago
Price Chart
Loading chart...
Executive Summary
Equillium announced a virtual investor event on May 27, 2026, to present new preclinical data on AhR modulators and the AhR/miR-124 axis. No clinical results were disclosed; the event is a research update that may provide insight into the mechanism of EQ504. The announcement is non-material without data.
Key Facts
- Virtual investor event scheduled for May 27, 2026, 11:00 AM ET.
- Event will feature new preclinical data on AhR modulators and the relationship between AhR activation and miR-124 induction.
- EQ504 is an investigational AhR modulator for ulcerative colitis and inflammatory lung diseases.
- The company seeks to resolve a paradoxical relationship between AhR and miR-124 that has remained controversial.
Financial Impact
No financial impact disclosed.
Risk Factors
- Preclinical data may not translate to clinical success.
- Conflict with published studies could limit mechanistic confidence.
- No timeline for clinical trials or regulatory milestones provided.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298855 |
13 reports for EQ
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+60 | — | — |
Oct 5, 2026 21d ago | 8-K | $1.42 | awaiting T+60 | — | $1.25 (−11.97%) |
Oct 5, 2026 21d ago | Press Release | $1.42 | awaiting T+60 | — | $1.25 (−11.97%) |
Sep 29, 2026 27d ago | Press Release | $1.63 | awaiting T+60 | — | $1.25 (−23.08%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.81 $2.21 | ▼ −21.35% | ▼ −25.75% | $1.25 (−55.52%) |
Jun 5, 2026 20w ago | Insider Cluster | $2.77 $2.21 | ▲ +20.40% | ▲ +23.45% | $1.25 (+54.87%) |
May 29, 2026 21w ago | Insider Cluster | $3.08 $2.18 | ▼ −29.22% | ▼ −30.45% | $1.25 (−59.42%) |
May 20, 2026 22w ago | Press Release | $2.21 | awaiting T+60 | — | $1.25 (−43.44%) |
Apr 17, 2026 27w ago | EFFECT | $2.05 $2.76 | ▲ +34.63% | ▲ +28.49% | $1.25 (−39.02%) |
Showing 10 of 13
US Market Status
Market Closed — Opens Wed (10h 31m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers